Important notice regarding Inveltys:
The board approved Inveltys (loteprednol etabonate ophthalmic suspension) 1% for addition to Rule 64B13-18.002. Effective August 5, 2019, Licensees are now permitted to prescribe Inveltys.
Important notice regarding Inveltys:
The board approved Inveltys (loteprednol etabonate ophthalmic suspension) 1% for addition to Rule 64B13-18.002. Effective August 5, 2019, Licensees are now permitted to prescribe Inveltys.
MQA is planning to revamp the board websites. Please take the survey to give us your recommendations by clicking the survey icon below. Survey closing Friday, 2/2/2024 at 4:30 PM ET Continue reading
An annual publication showcasing trends and information about Florida’s health care regulatory landscape. Continue reading